A Clinical Study to Evaluate the Long-term Safety of HRS-1893 in Hypertrophic Cardiomyopathy
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.
Also called NCT07021963
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 300 participants
- Registry
-
NCT07021963
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07021963. Non-randomized; no masking; primary purpose treatment. Start 2025-07-04 (actual); primary completion 2027-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Clinical Study to Evaluate the Long-term Safety of HRS-1893 in Hypertrophic Cardiomyopathy
- Condition
- Hypertrophic Cardiomyopathy
- Intervention (Drug)
- HRS-1893 Tablet
- Lead sponsor
- Shandong Suncadia Medicine Co., Ltd.
Record details
- Record id
cardio:ct-nct07021963- Content hash
d45894e79327e2aa6aa2b3d71f03e291b4a59f622187bcc68bd41363ab8ae80d